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Introduction
Chronic heart failure (CHF) is independently associated with 
several comorbid conditions, which in turn are also indepen-
dent contributors to CHF. From the clinical and research per-
spectives, CHF and associated comorbidities are often treated 
as independent pathologies despite increasing evidence of sig-
nificant overlap. Similarly, randomized controlled trials (RCTs) 
on CHF often exclude all but the mildest forms of any comor-
bidity and enroll a restricted patient demographic, which may 
limit the generalizability of findings to the “real world”.1 This 
is problematic considering that comorbidities are common in 
CHF, the presence of which may alter the pathophysiology and 
response to treatments.2 Changes to CHF guidelines reflect 
a growing awareness of these issues; however, the efficacy of 
CHF treatment in comorbid settings remains poorly under-
stood. Phase IV trials, which involve postmarketing surveil-
lance of the uncontrolled treatment of a patient population, are 
needed to advance understanding of external validity.3–5
In this review, we have focused on patient demograph-
ics, diabetes mellitus (DM), chronic renal failure (CRF), and 
atrial fibrillation in CHF. Pathophysiological variations in 
responses to treatments are seen for the following factors: 
doses (eg, statin doses and Asian patients), class of agents used 
(eg, benefits of nitrates and hydralazine for CHF in African 
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AbstrAct
bAckground: Beta-blockers (BBs) are the mainstay prognostic medication for all stages of chronic heart failure (CHF). There are many classes of 
BBs, each of which has varying levels of evidence to support its efficacy in CHF. However, most CHF patients have one or more comorbid conditions 
such as diabetes, renal impairment, and/or atrial fibrillation. Patient enrollment to randomized controlled trials (RCTs) often excludes those with certain 
comorbidities, particularly if the symptoms are severe. Consequently, the extent to which evidence drawn from RCTs is generalizable to CHF patients has 
not been well described. Clinical guidelines also underrepresent this point by providing generic advice for all patients. The aim of this review is to examine 
the evidence to support the use of BBs in CHF patients with common comorbid conditions.
Methods: We searched MEDLINE, PubMed, and the reference lists of reviews for RCTs, post hoc analyses, systematic reviews, and meta-analyses 
that report on use of BBs in CHF along with patient demographics and comorbidities.
results: In total, 38 studies from 28 RCTs were identified, which provided data on six BBs against placebo or head to head with another BB agent in 
ischemic and nonischemic cardiomyopathies. Several studies explored BBs in older patients. Female patients and non-Caucasian race were underrepresented 
in trials. End points were cardiovascular hospitalization and mortality. Comorbid diabetes, renal impairment, or atrial fibrillation was detailed; however, 
no reference to disease spectrum or management goals as a focus could be seen in any of the studies. In this sense, enrollment may have limited more severe 
grades of these comorbidities.
conclusIons: RCTs provide authoritative information for a spectrum of CHF presentations that support guidelines. RCTs may provide inadequate 
information for more heterogeneous CHF patient cohorts. Greater Phase IV research may be needed to fill this gap and inform guidelines for a more global 
patient population.
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American patients),6 or a particular agent within a class (eg, 
the lack of effect of bucindolol in African American patients).7 
Specifically, in the case of beta-blockers (BBs), there are intrin-
sic differences in pharmacology due to receptor selectivity, 
pharmacogenomics, and peripheral vasodilatory capacity. All 
these points have the potential to influence therapy for dif-
ferent groups of patients or those with a particular comorbid-
ity. These points have been previously well discussed.8–10 The 
presence of common comorbidities, such as DM and CRF, 
can affect the size of the treatment effect and, particularly in 
relation to CRF, the size and safety of the dosing regime.11,12 
These points may guide selection of one agent in a class over 
another or indicate the need for different treatment protocols. 
For these reasons, it is important that clinical demographics 
and comorbidities be representative, if not in the RCT but in 
subsequent postmarketing tools, such as post hoc analyses, sys-
tematic reviews, and meta-analyses, or with actual surveillance 
during Phase IV effectiveness and cost-effectiveness research. 
In this review, we examine the efficacy of BBs in CHF patients 
with particular focus on hetergeneous demographic cohorts 
and comorbid conditions.
Methods
eligibility criteria. RCTs, as well as reviews/meta-
 analyses of RCTs, which met the following criteria, were 
included: (i) head-to-head comparison of a BB with placebo, 
another BB, or another agent, irrespective of baseline therapy; 
(ii) a minimum of 50 patients in total; (iii) incidence of death 
as a reported end point; (iv) incidence of cardiac and noncar-
diac events as reported end points; (v) clinical follow-up of at 
least three months; and (vi) peer-reviewed journal publications 
before December 1, 2015, indexed in MEDLINE.
data sources and search. We searched for RCTs in MED-
LINE (1966–2015), PubMed, EMBASE, Scopus, and Cochrane 
databases, in addition to hand-searching the biblio graphies of iden-
tified studies for additional references. We restricted our searches 
to English language, human studies, clinical trials, and controlled 
clinical trials. We used the keywords and medical subject headings 
“heart failure” and “chronic” or “congestive” and “beta-blockers” or 
“adrenergic beta-antagonists”. To the results of this core search, we 
added the additional keyword “clinical trials” as the first criterion. 
From the core search history, secondary searches were conducted, 
limiting studies to post hoc analyses, meta-analyses, and reviews, 
with the keywords “diabetes mellitus”, “renal failure”, “atrial fibril-
lation”, or “race” to identify posttrial studies. We also searched 
using the individual BB names “bisoprolol”, “bucindolol”, “carve-
dilol”, “metoprolol”, and nebivolol” in the secondary search.
study collection and data extraction. The first author 
performed the scan of articles by title and abstract and then 
analyzed each of the short-listed studies. We reviewed the 
methodological quality of the studies using standard crite-
ria.13,14 The first author performed the data extraction, which 
included the following factors: age, sex, race, follow-up dura-
tion, New York Heart Association (NYHA) class, left ven-
tricular ejection fraction (LVEF), DM, CRF, hypertension, 
ischemia, atrial fibrillation, and all-cause mortality.
results
In total, 764 citations, four BB reviews,15–18 and the references 
in the relevant articles were screened for RCTs meeting the 
Additional records identified
from database search as
reviews of ββ on HF (n = 4
reviews and 50 citations)  
Records identified
through database search
(n = 764)
Records screened after
duplicates removed
(n = 781)   
Full text article assessed
for eligibility (n = 50)  
Studies included in
primary quantitative and
qualitative analysis (n = 38)
Studies included in
secondary analysis (n = 17)
Additional records identified
from database and other
sources on posthoc analysis, 
comorbidity correlates (n = 17) 
Records excluded (n = 731)
as not RCT, laboratory
studies, assessed variable 
outcomes   
Full text articles excluded
as not meeting inlusion
criteria (n = 12)  
Figure 1. search strategy. 
Abbreviations: ββ, beta-blocker; rCt, randomized controlled trial.
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inclusion criteria. From among 50 articles, 38 articles were 
included19–56 and 12 were excluded as not meeting the high-
lighted criteria.57–68 Additionally, 20 post hoc analyses, sys-
tematic reviews, and meta-analyses were identified in the 
secondary search and search of references (Table 1).69–87
general description. Six BBs with varying cardiac 
speci ficity and extracardiac properties were tested in the stud-
ies identified. Two BBs were found to have established vasodi-
latory properties. The majority of the studies compared BBs to 
placebo, with one larger study comparing two established BBs 
head to head. Nearly all studies recruited CHF cases ranging 
from mild to severe, with representation of the entire spectrum 
of illness within each study. In many cases, the enrollment to 
NYHA class tended to be better than the corresponding EFs. 
Most studies addressed one or more of the following themes: 
the effects of BB with baseline heart failure (HF) either mild 
or severe; safety, efficacy, and optimal methods for deriving 
clinical benefit; utility in ischemic and nonischemic etiologies; 
and benefits for older CHF cohorts. The mean age of par-
ticipants generally ranged between 50 years and 70 years, and 
no strict criteria were placed on excluding older participants. 
The SENIORS study, however, specifically enrolled patients 
older than 70 years of age, achieving a cohort mean age of 
76 ± 4.7 years.52 Post hoc data were also provided by MERIT-
HF.87 Females were generally underrepresented, with only 
four studies enrolling at least one-third of female. Seven stud-
ies described patient ethnicity, five of which predominantly 
enrolled Caucasians. In the BEST study, 627 (23%) of 2,708 
patients were African American, 143 (6%) Hispanic, and 42 
(2%) listed as other. In this demographically diverse cohort, 
the study objectives were not achieved.25 A smaller study with 
the same agent, which did not disclose racial demography, 
however, demonstrated safety and efficacy.24
etiology and comorbidities. Ischemic cardiomyopathy 
as etiology, coronary artery disease as comorbidity, and revas-
cularization strategies were listed in 26 studies. In more than 
half the studies, at least 50% of participants had ischemic 
heart disease. More than two-thirds of trials reported hyper-
tension as the etiology or a comorbidity of CHF. We explore 
three specific comorbidities in greater detail.
Diabetes. Eighteen trials listed concomitant diabetes. In 
most cases, the number of diabetics was between 18% and 
40%. In the BEST trial, 36% of participants were diabetic. 
This study also provided greater details on the comorbidity, 
with 964 (35.5%) of 2,708 participants diabetic, 398 (15%) 
on insulin, and 313 (12%) with end-organ complications. In 
a meta-analysis of seven trials, wherein 1,411 (25%) of 5,757 
participants had diabetes, Bell et al showed evidence for benefit 
with carvedilol in all groups, specifically, a reduction in rela-
tive risk (RR) of 28% (95% confidence interval [CI]: 3%–46%; 
P = 0.03] in diabetics.69 Haas et al compared four different 
BBs from six studies and noted similar prognostic benefits for 
treated diabetics (RR: 0.84; 95% CI: 0.73–0.96; P = 0.011); 
however, the magnitude of benefit was less compared to that 
in nondiabetics, (RR: 0.72; 95% CI: 0.65–0.79; P , 0.001).70 
Finally, post hoc analyses in MERIT-HF showed a 76% 
higher risk of hospitalizations for HF; however, a mortality 
benefit from metoprolol was only seen when the data were 
pooled with those from the CIBIS II and COPERNICUS 
trials, due to the small sample size.71,72
Renal impairment. Renal function and renal impairment 
were presented in a limited number of studies, mostly present-
ing data as mean serum creatinine. In the CIBIS III trial, 182 
(18%) of 1,010 of participants were reported as having a history 
of renal disease. Mean serum creatinine was 101 µmol/L, and 
estimated glomerular filtration rate (eGFR) was not detailed. 
Post hoc analysis of the SENIORS trial showed that eGFR 
was strongly associated with outcomes and that nebivolol 
was equally efficacious across low-, middle-, or high-eGFR 
(,55.5, 55.5–72.8, or .72.8 mL/min/1.73 m2) tertiles. In the 
low eGFR group to the high, the primary outcome (all-cause 
mortality or cardiovascular hospitalization) was reported in 
282 (40%) of 704 patients (hazard ratio [HR]: 0.81; 95% CI: 
0.64–1.03; P = 0.087), 218/704 (31%) patients (HR: 0.83; 
95% CI: 0.63–1.08; P = 0.164), and 202/704 (29%) patients 
(HR: 0.93; 95% CI: 0.70–1.22; P = 0.597). There were higher 
rates of drug discontinuation due to bradycardia in the mod-
erate-eGFR group.54 In a post hoc analysis of CIBIS II trial, 
849/2,647 (32%) participants who had eGFR ,60 mL/min 
were more likely to die or be hospitalized (RR: 0.66; 95% CI: 
0.5–0.88). All participants showed equal benefit with biso-
prolol. Treatment withdrawals were higher, as was mortality, 
with reducing renal function, more so the 63/2,584 patients 
with eGFR ,30 mL/min, with HR = 0.59 (95% CI: 0.30–
1.18), compared to 0.68 (95% CI: 0.56–0.83) for patients with 
eGFR .30 mL/min.73 In a post hoc analysis of MERIT-HF, 
493/3,965 (12%) were identified with low eGFR ,45 mL/
min, 976/3,965 (25%) had moderate eGFR 45–60 mL/min, 
and 2,496/3,965 (63%) had high eGFR. Metoprolol had dif-
fering efficacy levels against placebo across eGFR tertiles, 
whereby the mortality and HF hospitalization risk were the 
greatest in the low-eGFR group (HR: 0.44; 95% CI: 0.31–
0.63; P = 0.0001) compared to the high-eGFR group (HR: 
0.75; 95% CI: 0.62–0.92; P = 0.05).74 Finally, in an eight-trial 
meta-analysis, Badve et al reported findings that also sup-
ported the benefit of BBs in terms of reducing risk of all-cause 
(RR: 0.72; 95% CI: 0.64–0.80) and cardiovascular mortal-
ity (RR: 0.66; 95% CI: 0.49–0.89), but with increased risk of 
bradycardia (RR: 4.92; 95% CI: 3.20–7.55) and hypotension 
(RR: 5.08; 95% CI: 3.48–7.41).75
Rate and rhythm. Atrial fibrillation was reported in 
10 studies, with rates of approximately 10%–20% of partici-
pants. With an older cohort, in the SENIORS and ENECA 
trials, between 25% and 35% had atrial fibrillation at base-
line.59,60 Kotecha et al extracted individual patient data from 
10 RCTs, where 3,066/18,254 (17%) had atrial fibrillation at 
baseline. Crude mortality rates were higher with atrial fibril-
lation (633/3,064; 21%) compared to 2,237/13,945 (16%) for 
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sinus rhythm after mean follow-up of 1.5 years (SD: 1.1 years). 
BB treatment did not lead to a significant mortality benefit in 
atrial fibrillation (RR: 0.97; 95% CI: 0.83–1.14; P = 0.73) as 
with sinus rhythm (RR: 0.73; 95% CI: 0.67–0.80; P , 0.01). 
The authors also did not find benefit across subgroups of age, 
sex, LVEF, NYHA class, heart rate, and baseline medical 
therapy.76 In an older meta-analysis, benefits of BB in prevent-
ing atrial fibrillation were highlighted77; however, in known 
atrial fibrillation and HF, a four study meta-analysis,78 and 
a post hoc analysis from CIBIS II22 supported the findings 
of Kotecha et al For heart rates, McAlister et al performed a 
meta-analysis that showed that for every 5 beats/min reduction, 
there was a concomitant 18% reduction (95% CI: 6%–29%) in 
risk of death.79
discussion
RCTs are the gold standard for delivering the foundations 
of therapy. Post hoc analyses, systematic reviews, and meta-
 analyses are postmarketing tools that help refine or make 
sense of the collective evidence. All the small and large RCTs 
using BBs in CHF have answered the question of safety and 
efficacy very well. Studies have set out to enroll cohorts with 
a good spectrum of illness severity, as detailed in the NYHA 
class and mean LVEF. To control for confounders, studies may 
have controlled the heterogeneity of the other demographic 
and comorbid variables. Why is this important? Guidelines 
are shaped around the findings of large RCTs, and appear to 
suggest that findings from these homogeneous studies apply 
equally to heterogeneous “real-world” patients. This may, in 
fact, be the case, although examples are presenting that a 
broader perspective may be needed.
Female sex and race have not received good representation 
in any RCT. Post hoc analysis from MERIT-HF and pooling 
of results with CIBIS II and COPERNICUS show similar 
survival in women and men.80,81 The BEST trial, with greater 
participant heterogeneity, showed significant differences in 
baseline clinical and laboratory characteristics, such as younger 
age, black race, higher nonischemic etiology, higher heart rate 
and left bundle branch block, and lower plasma noradrenaline 
levels, where the prognostic predictive variables also varied 
in magnitude between females and males.82 In another post 
hoc analysis using the BEST study population, the authors 
achieved conformity with the CIBIS-II and MERIT-HF 
trials, including matching of the racial demographics, and 
were able to show that bucindolol treatment was associated 
with significantly lower mortality, raising the possibility of 
subgroup differences in responses to BBs.15 Possible explana-
tions include difference in disease pathophysiology, different 
baseline noradrenaline levels, functional polymorphisms of 
β-adrenergic receptors, or more advanced disease at base-
line, ie, higher risk. However, for carvedilol, in the USCHF 
trials, 217/1,004 African American patients and a further 
121 from the COPERNICUS trial showed significant mor-
tality benefits.7,83 The African American Heart Failure Trial 
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(AHeFT) has highlighted the benefits of vasodilatory therapy 
in this group.88 Whether BBs as a class or intrinsic differences 
between agents have effects on diverse communities must be 
the focus of future Phase IV research.89,90
BB therapy is underutilized for both HF and diabetes, as 
well as the latter’s complication such as nephropathy, despite 
evidence of sympathetic system overactivity, partly due to 
historical concerns of tolerability, adverse hemodynamic and 
metabolic effects, and lack of selectivity of BBs. Heterogeneity 
within the same class of BBs perhaps poses the greatest chal-
lenge in its use. Arguably, vasodilating BBs such as carvedilol 
and nebivolol offer the opportunity to study whether theoreti-
cal benefits translate to real-world improvements in metabolic 
profiles and renal function as they reduce insulin resistance and 
do not adversely interfere with blood glucose control.77,91 Haas 
et al noted that 24.6% of diabetic subjects from six studies using 
bisoprolol, metoprolol, and carvedilol (ANZHFRCG, BEST, 
CIBIS-II, COPERNICUS, MERIT-HF, and USCHFSG) 
appeared to derive benefits from BB therapy, although the 
magnitude of benefit was less than that achieved in non-DM 
subjects.78 In the MERIT-HF study, diabetics had a 76% 
higher risk of hospitalization, and this risk was significantly 
reduced with metoprolol, although considering the small sam-
ple size, a mortality benefit was not shown.22,79 However, with 
carvedilol, a seven-study meta-analysis, wherein 25% of 5,757 
patients had diabetes, showed similar survival benefits between 
the different subclasses.80 In the COMET study, which com-
pared carvedilol and metoprolol, the diabetics, who comprised 
24% of the patients, did not reach statistical significance.79,86 
Published RCTs have not conclusively addressed the question 
of whether a BB class is superior in CHF with comorbid DM, 
and this remains an area for Phase IV trials.
Autonomous sympathetic overactivity and susceptibility 
to iatrogenic peripheral vasoconstriction are several consider-
ations in cardiorenal syndrome. In the latter, first-generation 
BBs, such as propranolol, which modulate at both β1 and β2 
receptors, pose the greatest risk to renal function by reducing 
cardiac output, and unopposed activation of α1-induced reflex 
increased sympathetic activity and peripheral resistance.92 
Even second-generation BBs such as metoprolol with smaller 
affinity for β2 receptors can increase renal vascular resistance, 
although not conclusively shown to alter renal function.93 
Similar to diabetics, higher grades of renal impairment were a 
limiting factor for enrollment.12 Data from MERIT-HF and 
CIBIS-II trials showed equal efficacy in reducing mortality 
and hospitalization with eGFR ,45 mL/min and .60 mL/
min for metoprolol and across all strata for bisoprolol, 
although, numerically, all-cause mortality did not improve 
with eGFR ,60 mL/min.84,85 Third-generation or vasodila-
tory BBs, however, increase cardiac output and renal blood 
flow while reducing renal vascular resistance. Post hoc analysis 
from SENIORS, trialling the vasodilatory BB nebivolol 
demonstrated that the relative benefits were similar in patients 
with and without renal impairment, perhaps highlighting 
a greater benefit in absolute terms.2,54 Pooled data of 4,217 
patients from the CAPRICORN and COPERNICUS tri-
als showed significantly improved outcomes for patients with 
eGFR between 45 mL/min and 60 mL/min, but not with 
eGFR ,45 mL/min.85 However, in a trial with 114 hemodi-
alysis-dependent patients, there was a statistically significant 
mortality benefit with carvedilol treatment.42 There is uni-
formity in the consensus that all grades of renal impairment 
require BB therapy; however, the optimal agent when faced 
with metabolic and cardiorenal syndromes awaits dedicated 
research. Even more importantly, in the Acute Decompensated 
Heart Failure National Registry (ADHERE) database, 63.6% 
of admitted patients were classified as having at least moder-
ate renal impairment, which in turn predicted other comorbid 
risks,12 flagging this area as needing greater focus.
The question of rate has a clear consensus, whereby lower 
rates do translate to better outcomes.79 The dose or the agents are 
vehicles in delivering this target; however, as all trials have used 
the maximal tolerated dose as a study criterion, this still remains 
the target in clinical settings. A rhythm-based strategy in atrial 
fibrillation and HF is less clear. The main pharmacological ther-
apies that are used in maintaining sinus rhythm are either con-
traindicated as with flecainide, not proven with sotalol, or have 
long-term toxicity concerns with amiodarone. Between 10% and 
35% of trial participants have comorbid atrial fibrillation, whereby 
the most recent 10-study meta-analysis could not demonstrate an 
outcome benefit with BBs.76 Interestingly, in seven studies with 
11,952 patients, BBs significantly reduced the incidence of atrial 
fibrillation from 39 to 28 per 1,000 patient-years, a 27% reduc-
tion of the RR (95% CI: 14–38; P , 0.001).77 Using a strategy 
of catheter ablation restored and maintained sinus rhythm, with 
concomitant improvement of cardiac function, cardiac dimen-
sions and quality of life.94,95 A randomized study of 1,376 patients, 
which excluded persistent atrial fibrillation and used cardioversion 
with amiodarone, sotalol, or dofetilide to maintain sinus rhythm, 
did not show significantly different results relative to the rate-con-
trolled arm.96 The finding from these, albeit relatively small, trials 
showing discrepancies in outcomes between the strategies, com-
pared to the larger study, does again raise the question of external 
validity and application of results. Again, population-level post-
trial studies must be used to monitor or even trial such strategies 
when there are no controls on the patients.
In summation, post hoc analysis has provided some 
insights into the interaction between BB treatments in HF 
for race and comorbid conditions. The results suggest that the 
RR reduction could be greater for those with more advanced 
disease compared to those on placebo. The results, however, 
do not provide any pathophysiological insights into the poten-
tial mechanism of benefit. They also do not provide insight 
into the additional benefits of using a particular class of BB 
with a theoretical benefit against a particular comorbidity, eg, 
vasodilatory BB in diabetics or renal impairment. What can 
be done? While there are robust postmarketing publications 
in the form of post hoc analyses, clinical reviews, or meta-
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analyses, actual postmarketing surveillance or Phase IV trials 
on effectiveness and cost-effectiveness appear to be less well 
conducted. Greater examples of such studies should be con-
ducted. The most feasible option for this would be using the 
prospective database from treating centers that would collect 
data from all treated patients. The more difficult part would 
be finding a method that allows these findings to sit alongside 
RCTs and thus be factored into guidelines relevant for a more 
global HF community and patient demography.
conclusion
A consistent process – from establishing safety and efficacy, 
to evaluating morbidity and mortality outcomes and posttrial 
subgroup or pooled analysis – has been established in the com-
parison of BB or placebo for systolic HF. Gaps exist in the 
recruitment of more heterogeneous patient cohorts, showing 
features such as ethinic diversity, comorbid conditions of dia-
betes, renal impairment, or sicker patients. With the need to 
remove confounders and maintain strong internal and exter-
nal validity in trial design, the potential for Phase IV studies, 
however, to expand on the validity does not appear to be met. 
The assessment of efficacy and cost-effectiveness is also lack-
ing. Future researchers and drug companies should continue to 
focus on delivering all levels of randomized controlled studies. 
Research groups or institutes and health systems should give 
greater emphasis on building robust Phase IV studies to better 
understand the safety, efficacy, and cost-effectiveness of proven 
therapies initially used in a controlled group, at the popula-
tion level. Clinical guidelines should similarly reflect potential 
problems with data from a homogeneous cohort for what is 
now a more global population being treated.
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